Section Arrow
Quote
ATOS.NASDAQ
- Atossa Therapeutics Inc.
Quotes are at least 15-min delayed:2026/02/23 16:38 EST
After Hours
Last
 3.96
0 (0.00%)
Bid
3.85
Ask
4.05
High 3.96 
Low 3.96 
Volume 3 
Regular Hours (Closed)
Last
 3.96
-0.25 (-5.94%)
Day High 
4.15 
Prev. Close
4.21 
1-M High
10.95 
Volume 
4.86K 
Bid
3.85
Ask
4.05
Day Low
3.835 
Open
4.11 
1-M Low
3.76 
Market Cap 
36.25M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.45 
20-SMA 6.16 
50-SMA 8.59 
52-W High 19.35 
52-W Low 3.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.45/-4.20
Enterprise Value
36.25M
Balance Sheet
Book Value Per Share
5.78
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.3935 -0.02705 -6.43%
ELABPMGC Holdings Inc.1.21-0.08-6.20%0.01PE
After Hours 1.2102 +0.0002 +0.02%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.76 -0.06 -0.61%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.22 +0.05 +0.61%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.79 -0.01 -0.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.